| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg | |||
| 5mg |
|
||
| Other Sizes |
| Targets |
The biological targets of 11-deoxy Prostaglandin F1alpha are the prostaglandin F receptor (FP receptor) and potentially other prostaglandin receptors (EP, DP, IP, TP) depending on the tissue. Prostaglandin F2alpha (PGF2alpha) and its analogs bind to FP receptors to mediate smooth muscle contraction, vasoconstriction, and bronchoconstriction. The removal of the 11-hydroxy group alters the binding affinity and selectivity compared to PGF1alpha.
|
|---|---|
| ln Vitro |
In whole animal studies, 11-deoxy PGF1alpha at a dose of 32 mg/kg inhibited gastric acid secretion by 35%. It is also known to cause rat uterine contractions at a dose 0.3 times that of PGF1alpha, indicating it is approximately three times more potent than the parent compound in this assay. The compound exhibits activity as a vasopressor (blood pressure-elevating) and a bronchoconstrictor. 11-deoxy PGF1alpha (0-10 mg/kg, intravenous) stimulates uterine contractions in pregnant rats.
|
| ln Vivo |
11-deoxy PGF1α (0-10 mg/kg, intravenous, single dose) stimulates uterine contractions in pregnant Sprague-Dawley rats and slightly affects fertility in hamsters [1].
11-deoxy PGF1alpha exhibits activity as a vasopressor and bronchoconstrictor, and causes uterine contractions. At a dose of 32 mg/kg, it inhibited gastric acid secretion by 35% in whole animal studies. It causes rat uterine contractions at a dose 0.3 times that of PGF1alpha, meaning it is approximately three times more potent than the parent compound in this assay. 11-deoxy PGF1alpha (0-10 mg/kg, IV) stimulates uterine contractions in pregnant Sprague-Dawley rats. |
| Enzyme Assay |
Not applicable. 11-deoxy Prostaglandin F1alpha is a prostaglandin analog, and its activity is typically measured in functional tissue assays rather than cell-free receptor binding. However, a typical FP receptor binding assay: Membrane preparations from cells expressing the FP receptor are incubated with 0.5-2 nM [3H]-PGF2alpha and varying concentrations of unlabeled 11-deoxy PGF1alpha (0.1-10,000 nM) in binding buffer (50 mM Tris-HCl pH 7.4, 10 mM MgCl2) at 25degC for 60 minutes. Bound radioactivity is separated by filtration, and IC50 is calculated.
|
| Cell Assay |
Standard cell-based assays for prostaglandin activity: FP receptor-expressing cells (e.g., Swiss 3T3 fibroblasts or HEK293 cells stably expressing FP receptor) are loaded with a calcium-sensitive dye (Fluo-4 AM) and treated with varying concentrations of 11-deoxy PGF1alpha (0.01 nM to 10 uM). Intracellular calcium mobilization is measured in a fluorescence plate reader. For IP1 or cAMP accumulation (if activating other prostaglandin receptors), cells are treated with compound for 30 minutes and cAMP is measured by HTRF or ELISA.
|
| Animal Protocol |
Animal/Disease Models: pregnant Sprague-Dawley rats[1]
Doses: 0-10 mg/kg Route of Administration: i.v., single dose Experimental Results: Stimulated uterine contraction 3 times active as PGF1α. For gastric acid secretion studies: Rats are fasted for 24 hours. Under anesthesia, the stomach is cannulated. 11-deoxy PGF1alpha is administered intravenously or intraperitoneally at doses ranging from 1-100 mg/kg. Gastric juice is collected for 1-2 hours, and the volume and acidity (titratable acid) are measured. For uterine contraction studies: Pregnant rats are anesthetized, and uterine horns are exposed. 11-deoxy PGF1alpha (0-10 mg/kg, IV) is administered, and uterine contractions are recorded using an isometric force transducer. |
| ADME/Pharmacokinetics |
No PK data was found for 11-deoxy Prostaglandin F1alpha. Prostaglandin analogs typically have very short half-lives in circulation (measured in minutes), as they are rapidly metabolized by 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and beta-oxidation. The compound is rapidly cleared from the bloodstream following intravenous administration.
|
| Toxicity/Toxicokinetics |
No specific toxicity data was found. 11-deoxy PGF1alpha is a prostaglandin analog and, like other prostaglandins, may produce dose-dependent side effects including bronchoconstriction (wheezing, difficulty breathing), vasoconstriction (hypertension), and gastrointestinal effects (nausea, diarrhea, abdominal cramps). At high doses, uterine contractions could pose risks in pregnant animals. Standard lab safety practices apply.
|
| References | |
| Additional Infomation |
11-Deoxyprostaglandin F1alpha is a prostaglandin. The references provided refer to the (9α,13E,15S)-isomer.
11-deoxy Prostaglandin F1alpha (11-deoxy PGF1alpha) is a research-grade prostaglandin analog with molecular formula C20H36O4 and molecular weight 340.50. Purity reported as ≥95%. It is a synthetic analog of PGF1alpha used as a research tool for studying prostaglandin biology, smooth muscle contraction, and gastric physiology. For research use only, not for human therapeutic applications. |
| Molecular Formula |
C20H36O4
|
|---|---|
| Molecular Weight |
340.50
|
| Exact Mass |
340.261
|
| CAS # |
37785-98-1
|
| PubChem CID |
5283069
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
507.2±40.0 °C at 760 mmHg
|
| Flash Point |
274.6±23.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
4.21
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
24
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCC[C@@H](/C=C/[C@H]1CC[C@@H]([C@@H]1CCCCCCC(=O)O)O)O
|
| InChi Key |
HYBPXYQCXNOTFK-DUSCRHDRSA-N
|
| InChi Code |
InChI=1S/C20H36O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12,14,16-19,21-22H,2-11,13,15H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+,19-/m0/s1
|
| Chemical Name |
7-[(1R,2S,5R)-2-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid
|
| Synonyms |
11-deoxy PGF1α
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9369 mL | 14.6843 mL | 29.3686 mL | |
| 5 mM | 0.5874 mL | 2.9369 mL | 5.8737 mL | |
| 10 mM | 0.2937 mL | 1.4684 mL | 2.9369 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
